iShares Core S&P Small-Cap

Jim Chanos, the founder and president of Kynikos Associates, is a long-time short-seller of Tesla stock. Tesla stock has fallen 17.5% in the last year.

On January 31, Aveo Pharmaceuticals (AVEO) issued a press release announcing its decision not to file an NDA for Fotivda (tivozanib).

Today, iRobot (IRBT) stock surged 5.3% before the market opened.

In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.

Flotek Industries (FTK) is 0.04% of the iShares Core S&P Small-Cap ETF (IJR). IJR increased 8% in the past year, versus a 56% decrease in FTK’s stock price during the period.

In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.

San Francisco–based biopharmaceutical company Nektar Therapeutics (NKTR) develops drug candidates that make use of its advanced polymer conjugate technology platforms.

Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.

In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.

Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.

On October 16, 2017, all analysts tracking Flotek Industries rated it as a “buy” or some equivalent.

In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.

The American economy is facing major structural issues that have the potential to thwart economic progress. The most important hurdle facing the US economy is an aging population.

Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.

In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

Flotek stock will likely close between $6.42 and $5.50 in the next seven days. Flotek’s stock price was $5.96 on August 10, 2017.

In 2Q17, Flotek Industries’ (FTK) total debt fell ~34% compared to 2Q16.

Flotek Industries’ (FTK) management expressed optimism about improving pricing for FTK’s complex nano-Fluid (or CnF) products despite higher raw material costs.

On July 3, 2017, Flotek’s (FTK) implied volatility was ~58%. Since its 1Q17 earnings were announced on May 3, 2017, FTK’s implied volatility has remained unchanged.

In 1Q17, Flotek Industries’ (FTK) total debt fell ~19% on a YoY basis. Its cash and marketable securities fell 26% during the same period.

Flotek’s management expects an optimum recovery in energy reservoirs by upstream operators, which has already started to push demand for FTK’s technology.

The short interest in Tidewater (TDW) stock as a percentage of its float was 27.6% as of January 18—compared to 37.3% as of September 30, 2016.

What does Flotek Industries’ management think? Flotek Industries’ (FTK) management believes the company resisted energy market weakness through steady performance in the energy chemistry segment. In the company’s 3Q16 conference call, Flotek Industries CEO John Chisholm stated that “we feel fortunate that our focus on high-end value added technology, especially in our energy chemistry segment […]

H.B. Fuller’s (FUL) Construction Products segment reported revenue of $64.4 million in 3Q16, which is 12.6% of the company’s total revenue.

Flotek Industries’ net debt-to-trailing 12 month adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) rose from 2Q15 to 2Q16.

Flotek Industries’ (FTK) management considers the current energy market environment to be challenging for the oilfield services industry.

Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.

Analysts have revised their estimated EBITDA margins for Papa John’s (PZZA) for next four quarters.

Richard Bernstein advises against trying to time the markets. What happens more often than not is that retail investors end up buying high and selling low—the opposite of what they should be doing.

Buffett said that it has been a terrible mistake to bet against America, not only for the past 240 years but even now. He believes that America’s emphasis on innovation and strength in commerce will continue to provide strong gains for its people.

A closer look at EdR’s (EDR) trailing-12-month price-to-FFO multiple shows that it is in line with its historical valuation.

Education Realty Trust is a self-managed and self-administered equity REIT. The main objective of the company is to develop, acquire, own, and manage student housing properties.

Fortunately for Century Aluminum, its leverage ratios are currently much lower than other companies in this space. CENX has $123 million in cash that should help it manage its operations over the next few quarters

Century Aluminum’s (CENX) consolidated shipments in 3Q15 were down 1% as compared to 2Q15. In 4Q14, CENX had acquired Alcoa’s stake in the Mt. Holly smelter.

Vasco Data Security (VDSI) has generated returns of -25.5% in the trailing 12 months and 3.0% in the trailing-one-month period.

AK Steel (AKS) reported its 2Q15 earnings on July 28. The company’s share price rose significantly after it released its second quarter results.

According to data released on May 25 by the WSA, world crude steel production totaled 135 million tons in April. This is a decline of 1.7% YoY.

This year, steel companies have had a mixed performance on Wall Street. However, there are signs of a revival in the steel industry.